Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Q1 2026 revenue $7.2 million, net loss $61.7 million

Negative Impact 3 of 5 earnings Written later

Generate Biomedicines reported first quarter 2026 results, with revenue of $7.2 million, down from $8.8 million a year earlier, and a net loss of $61.7 million, up from $44.3 million. Cash, cash equivalents and marketable securities rose to $516.6 million after its March 2, 2026 IPO, which the company says funds operations into the first half of 2028, though it expects to need additional capital.

Key points

  • Revenue was $7.2 million for the quarter ended March 31, 2026, compared with $8.8 million a year earlier, tied to Amgen and Novartis research programs.
  • Research and development expenses rose to $57.8 million from $46.8 million, driven mainly by the GB-0895 Phase 3 program in severe asthma.
  • Cash, cash equivalents and marketable securities were $516.6 million at March 31, 2026, versus $221.5 million at December 31, 2025, including $369.3 million in net IPO proceeds.
  • Net cash used in operating activities was $80.4 million, compared with $53.2 million a year earlier.

The filing

CompanyGenerate Biomedicines, Inc. (GENB)
Form8-K, current report
Filed with the SECMay 7, 2026, 6:00 AM ET
Accession number0001193125-26-209899

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.